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ScoOBJECTIVES The purpose of this study was to examine the treatment effect of vericiguat in relation to N-terminal
pro-B-type natriuretic peptide (NT-proBNP) levels at randomization.
BACKGROUND Vericiguat compared with placebo reduced the primary outcome of cardiovascular death (CVD) or heart
failure hospitalization (HFH) in patientswithHFwith reducedejection fraction (HFrEF) in theVICTORIA (A Study ofVericiguat
in Participants With Heart Failure With Reduced Ejection Fraction) trial. Because an interaction existed between treatment
and the primary outcome according to pre-specified quartiles of NT-proBNP at randomization, we examined this further.
METHODS This study evaluated the NT-proBNP relationship with the primary outcome in 4,805 of 5,050 patients as a
risk-adjusted, log-transformed continuous variable. Hazard ratios (HRs) and 95% confidence intervals (CIs) are
presented.
RESULTS Median NT-proBNP was 2,816 pg/ml (25th to 75th percentile: 1,556 to 5,314 pg/ml). The study treatment
effect varied across the spectrum of NT-proBNP at randomization (with log2 transformation, p for interaction ¼ 0.002). A
significant association between treatment effects existed in patients with levels <4,000 pg/ml and remained evident up
to 8,000 pg/ml. A 23% relative risk reduction occurred in the primary endpoint with NT-proBNP #4,000 pg/ml (HR:
0.77; 95% CI: 0.68 to 0.88). For NT-proBNP values #4,000 pg/ml (n ¼ 3,100), the HR was 0.78 (95% CI: 0.67 to 0.90)
for HFH and 0.75 (95% CI: 0.60 to 0.94) for CVD. For NT-proBNP #8,000 pg/ml (n ¼ 4,133), the HR was 0.85 (95% CI:
0.76 to 0.95) for the primary outcome, 0.84 (95% CI: 0.75 to 0.95) for HFH, and 0.84 (95% CI: 0.71 to 0.99) for CVD.
For NT-proBNP >8,000 pg/ml (n ¼ 672), the HR was 1.16 (95% CI: 0.94 to 1.41) for the primary outcome.
CONCLUSIONS A reduction in the primary composite endpoint and its CVD and HFH components was observed in
patients on vericiguat compared with subjects on placebo with NT-proBNP levels up to 8,000 pg/ml. This provided new
insight into the benefit observed in high-risk patients with worsening HFrEF. (A Study of Vericiguat in Participants With
Heart Failure With Reduced Ejection Fraction [HFrEF] [MK-1242-001] [VICTORIA]; NCT02861534)
(J Am Coll Cardiol HF 2020;8:931–9) © 2020 The Authors. Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 2213-1779 https://doi.org/10.1016/j.jchf.2020.08.008
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ABBR EV I A T I ON S
AND ACRONYMS
CI = confidence interval
CVD = cardiovascular death
HF = heart failure
HFH = heart failure
hospitalization
HRrEF = heart failure with
reduced ejection fraction
HR = hazard ratio
MAGGIC = Meta-Analysis
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932T he measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a cornerstone for diag-
nosis, risk stratification, and follow-up of pa-
tients with heart failure (HF) (1).
Accordingly, NT-proBNP levels have been
widely used as an inclusion criterion for clin-
ical trials and as surrogate metrics within
studies to gauge the relationship between
the treatment effect on this biomarker and
overall outcomes (2). Because patient, trial,
mechanism of treatment, or other factors
may modulate the relationship between
natriuretic peptides and outcomes, further
understanding of these relationships iscrucial for the interpretation of interventions and
their impact on outcomes.
ideSEE PAGE 940The VICTORIA (A Study of Vericiguat in Partici-
pants With Heart Failure With Reduced Ejection
Fraction) trial evaluated vericiguat compared with
placebo in high-risk patients with HF and reduced
ejection fractions (HFrEFs) who had a recent HF hos-
pitalization (HFH) or intravenous diuretic therapy.
The primary findings were a reduction in the primary
composite outcome of cardiovascular death (CVD) or
HFH with vericiguat compared with placebo (3). In a
pre-specified subgroup analysis, a significant inter-
action was noted between NT-proBNP quartiles at
randomization and the primary endpoint. Specifically,
those patients in the highest quartile of NT-proBNP
(>5,314 pg/ml) appeared to have less benefit from
vericiguat compared with placebo; conversely, those
in the lowest 3 quartiles derived greater benefit from
vericiguat compared with placebo. Caution must be
exercised in interpreting treatment effects from such
subgroups because of the uncertainties about their
biological plausibility versus the play of chance (4).
To further understand the NT-proBNP subgroup
results, we explored the relationship of NT-
proBNP across the spectrum of levels at randomiza-
tion with the treatment effect of vericiguat compared
with placebo in the VICTORIA trial. We also described
the relationship of other baseline factors that poten-
tially modified the interpretation of this pre-specified
NT-proBNP subgroup interaction.s attest they are in compliance with human studies committe
and Food and Drug Administration guidelines, including patien
CC: Heart Failure author instructions page.
received August 3, 2020; accepted August 4, 2020.METHODS
STUDY PATIENTS. The design, baseline characteris-
tics, and results of the VICTORIA trial were previously
published (3,5,6). In brief, the trial included 5,050
patients with worsening chronic HF (New York Heart
Association functional classes II to IV), a left ven-
tricular EF <45%, elevated natriuretic peptide levels,
and recent HF decompensation. Patients were
randomly assigned in a 1:1 ratio to receive vericiguat
or placebo. Patients in sinus rhythm had to have
BNP $300 pg/ml or NT-proBNP $1,000 pg/ml; pa-
tients with atrial fibrillation had to have BNP $500
pg/ml or NT-proBNP $1,600 pg/ml. Guideline-based
HF therapies were encouraged before inclusion,
including sacubitril/valsartan. The trial protocol was
approved by regulatory agencies in participating
countries, as well as the ethics committees and
institutional review boards at participating sites. All
patients provided written informed consent.
NATRIURETIC PEPTIDE ASSESSMENT. Of the 5,050
participants in VICTORIA, 245 did not have an
evaluable NT-proBNP at randomization, leaving a
remaining 4,805 patients for analysis (Supplemental
Table 1). Per protocol, NT-proBNP was measured by
a central laboratory on the Roche Elecsys assay
(Roche Diagnostics, Mannheim, Germany). Analytical
range of the assay was 10 to 175,000 pg/ml.
CLINICAL OUTCOMES. The primary outcome of
VICTORIA was the composite endpoint of time to
CVD or first HFH. We also explored the individual
components of the composite outcomes (CVD and
HFH). All clinical outcomes observed up to the
primary analysis cutoff date (June 18, 2019)
were included.
STATISTICAL ANALYSIS. The distribution of NT-
proBNP was right skewed, with values ranging from
10 to 175,000 pg/ml. The relationship of NT-proBNP
(as a continuous variable) to the primary composite
outcome was assessed using the restricted cubic
spline with 4 knots (7) and was observed to be
nonlinear (p < 0.001) (Supplemental Figure 1). We
transformed NT-proBNP on a logarithmic scale (base
2), revealing a linear relationship with the log-hazard
of the primary outcome. The relative risk change in
this transformed variable was interpreted as peres and animal welfare regulations of the authors’
t consent where appropriate. For more information,
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933doubling of NT-proBNP. To estimate these relative
associations with the clinical outcomes, Cox propor-
tional hazard models were used, and hazard ratios
(HRs) and 95% confidence intervals (CIs) were re-
ported, along with absolute risk reduction. We
anticipated differences in the patient characteristics
across the spectrum of NT-proBNP at randomization.
Therefore, associations with clinical outcomes were
stratified for region and/or race and reported as un-
adjusted and adjusted for the modified Meta-Analysis
Global Group in Chronic Heart Failure (MAGGIC) risk
score (6,8). We also explored broader adjustment
using an internally validated set of variables from
VICTORIA for the primary composite endpoint and
CVD, which contained 16 and 19 covariates, respec-
tively (Supplemental Table 2A). A description of the
patient characteristics that are in the VICTORIA pre-
diction models but do not appear in Table 1 are pro-
vided in Supplemental Table 2B. The interaction of
the randomized study treatment assignment (ver-
iciguat or placebo) with NT-proBNP at randomization
was included in the models, and p values for the in-
teractions were reported).
Cut points were approximated from the treatment
effect across the spectrum of (log-transformed)
NT-proBNP, in which the upper confidence limit
of the treatment effect did not include 1.00 (i.e.,
4,000 pg/ml) and below which the point estimate of
the treatment effect was <1.00 (i.e., 8,000 pg/ml).
These cut points were then used to summarize the
relative treatment estimate (HR; 95% CI) above and
below these values. To provide context to these find-
ings, patient characteristics were summarized accord-
ing to #4,000, >4,000 to 8,000, and >8,000 pg/ml.
These characteristics are also provided according
to quartiles of NT-proBNP in the Supplemental
Appendix. Median (25th to 75th percentiles) for
continuous variables and frequency (percentages) for
categorical variables were used to summarize data.
Patients with missing values of NT-proBNP
(n ¼ 245) at randomization were excluded from the
present study, and their data were not imputed
(Supplemental Table 1). Data for patients with a
missing MAGGIC score (71 of 4,805 patients) were not
imputed, and these patients were excluded from the
risk-adjusted analyses. All analyses were performed
using SAS version 9.4 (SAS Institute, Inc., Cary, North
Carolina). A 2-sided test result with p < 0.05 was
considered statistically significant.
RESULTS
TREATMENT EFFECT OF VERICIGUAT COMPARED
WITH PLACEBO BY BASELINE NT-proBNP. Therelationship between NT-proBNP as a continuous
variable and the treatment effect of vericiguat on the
primary composite outcome is shown in Central
Illustration A. The histograms within this
Figure depict the distribution of patients by NT-
proBNP intervals of 1,200 pg/ml. Across the spec-
trum of NT-proBNP levels, there was an association of
the treatment effect up to 8,000 pg/ml (Supplemental
Figures 2A and 2B). This association of treatment ef-
ficacy with vericiguat, compared with placebo, on the
primary outcome was further estimated at 4,000 pg/
ml (HR: 0.90; 95% CI: 0.82 to 0.99) (Supplemental
Figure 2A). The treatment effect on the primary
outcome for patients with NT-proBNP #4,000 pg/ml
and those with >4,000 pg/ml produced HRs of 0.77
(95% CI: 0.68 to 0.88) and 1.05 (95% CI: 0.92 to 1.20),
respectively (Table 2). These and the following find-
ings were confirmed after adjustment for prediction
models developed in the VICTORIA trial
(Supplemental Table 3). The individual components
of the primary outcome were similarly affected
(Central Illustration B and C, Supplemental Figures 3
and 4) in patients with NT-proBNP levels #4,000
pg/ml at randomization for CVD (HR: 0.75; 95% CI:
0.60 to 0.94) and HFH (HR: 0.78; 95% CI: 0.67 to 0.90)
(Table 2). These HRs corresponded to absolute risk
reductions of 6.8, 1.3, and 5.5 events per 100 patient-
years for the primary composite endpoint, CVD, and
HFH, respectively.
Further exploration of this relationship showed an
association of the treatment effect with vericiguat on
the primary outcome in NT-proBNP levels extended
to 8,000 pg/ml. The components of the primary
outcome were associated with a significant effect for
CVD (HR: 0.84; 95% CI: 0.71 to 0.99) and HFH (HR:
0.84; 95% CI: 0.75 to 0.95) (Table 2). These HRs cor-
responded to absolute risk reductions of 5.4, 0.8, and
4.6 events per 100 patient-years for the primary
composite endpoint, CVD, and HFH, respectively.
When NT-proBNP values >8,000 pg/ml were
analyzed, this association of treatment benefit was no
longer evident for the primary outcome (HR: 1.16;
95% CI: 0.94 to 1.41), CVD (HR: 1.32; 95% CI: 1.01 to
1.71), or HFH (HR: 1.17; 95% CI: 0.92 to 1.48). When
these outcomes for NT-proBNP values >8,000 pg/ml
were adjusted using the VICTORIA prognostic model
(Supplemental Table 3), the respective HRs were 1.10
(95% CI: 0.90 to 1.35) for the primary outcome, 1.27
(95% CI: 0.97 to 1.66) for CVD, and 1.11 (95% CI: 0.87
to 1.41) for HFH.
To provide clinical context, the patient charac-
teristics according to NT-proBNP categories (#4,000,
>4,000 to 8,000, >8,000 pg/ml) at randomization
are shown in Table 1. Patients with higher NT-
TABLE 1 Baseline Characteristics of Patients by NT-proBNP at Randomization
NT-proBNP at Randomization (pg/ml)
#4,000 (n ¼ 3,100) >4,000 to 8,000 (n ¼ 1,033) >8,000 (n ¼ 672)
Age, yrs 67.0 (59.075.0) 70.0 (62.078.0) 70.0 (62.079.0)
Male 2,361 (76.2) 803 (77.7) 482 (71.7)
Race
White 1,967 (63.5) 639 (61.9) 426 (63.4)
Black 148 (4.8) 57 (5.5) 27 (4.0)
Asian 730 (23.5) 237 (22.9) 151 (22.5)
Other 254 (8.2) 100 (9.7) 68 (10.1)
Geographic region
Eastern Europe 1,023 (33.0) 367 (35.5) 212 (31.5)
Western Europe 501 (16.2) 173 (16.7) 134 (19.9)
Asia Pacific 756 (24.4) 246 (23.8) 159 (23.7)
Latin America 454 (14.6) 147 (14.2) 106 (15.8)
North America 366 (11.8) 100 (9.7) 61 (9.1)
Index event
HF hospitalization within 3 months 1,972 (63.6) 757 (73.3) 486 (72.3)
HF hospitalization 3 to 6 months 562 (18.1) 156 (15.1) 103 (15.3)
IV diuretic for HF (without hospitalization) within 3 months 566 (18.3) 120 (11.6) 83 (12.4)
BMI, kg/m2 27.6 (24.231.7) 25.9 (23.129.9) 25.4 (22.528.7)
Medical history
Ejection fraction, % 30.0 (24.036.0) 27.0 (20.035.0) 26.0 (20.034.0)
Ejection fraction <40% 2,603 (84.1) 911 (88.4) 599 (89.5)
NYHA functional class at baseline
I 1 (0.0) 0 (0.0) 1 (0.1)
II 1,998 (64.5) 546 (52.9) 290 (43.2)
III 1,075 (34.7) 469 (45.4) 361 (53.7)
IV 26 (0.8) 18 (1.7) 20 (3.0)
Systolic blood pressure, mm Hg 119.0 (109.0131.0) 117.0 (107.5130.0) 120.0 (108.0133.0)
Diastolic blood pressure, mm Hg 73.0 (65.080.0) 71.0 (64.080.0) 72.0 (65.081.0)
Heart rate, beats/min 71.0 (63.080.0) 72.5 (64.082.0) 73.0 (65.084.0)
Atrial fibrillation 1,307 (42.2) 519 (50.2) 312 (46.4)
Diabetes mellitus 1,420 (45.8) 492 (47.6) 342 (50.9)
COPD 529 (17.1) 169 (16.4) 119 (17.7)
CAD 1,794 (57.9) 608 (58.9) 402 (59.8)
History of smoking 1,852 (59.7) 590 (57.1) 375 (55.8)
Time from diagnosis of any HF to randomization, yrs 3.3 (1.07.4) 3.3 (1.17.5) 3.0 (1.07.3)
Standard of care therapy
ACE-I or ARB 2,358 (76.1) 747 (72.3) 435 (64.7)
Sacubitril/valsartan 460 (14.8) 129 (12.5) 95 (14.1)
Beta blocker 2,904 (93.7) 957 (92.6) 610 (90.8)
MRA 2,275 (73.4) 700 (67.8) 414 (61.6)
Triple therapy 1,993 (64.3) 571 (55.3) 310 (46.1)
ICD 854 (27.6) 291 (28.2) 179 (26.6)
Biventricular pacemaker 431 (13.9) 158 (15.3) 105 (15.6)
Continued on the next page
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934proBNP levels tended to be older, were in a higher
New York Heart Association functional class, and
had a lower body mass index, ejection fraction, and
estimated glomerular filtration rates (Table 1). In
addition, they were more likely to be enrolled
earlier after index HFH. Although atrial fibrillation,
baseline device, and beta-blocker use were
similar across the NT-proBNP spectrum, lower rates
of angiotensin-converting enzyme inhibitors,angiotensin receptor blockers, and mineralocorticoid
receptor antagonists use were evident for patients
within the upper strata of NT-proBNP values. The
median MAGGIC risk score was lower among the
cohort with NT-proBNP values #4,000 pg/ml than
that in the other 2 groups.
These findings were in concert with those based on
the pre-specified subgroup analysis of quartiles of
NT-proBNP, which indicated higher risk patients in
TABLE 1 Continued
NT-proBNP at Randomization (pg/ml)
#4,000 (n ¼ 3,100) >4,000 to 8,000 (n ¼ 1,033) >8,000 (n ¼ 672)
Laboratory results
Hemoglobin, g/dl 13.7 (12.414.9) 13.0 (11.614.3) 12.5 (11.213.9)
Sodium, mEq/l 140.0 (138.0142.0) 140.0 (138.0142.0) 140.0 (138.0142.0)
Potassium, mEq/l 4.5 (4.24.8) 4.5 (4.24.9) 4.4 (4.14.9)
eGFR, ml/min/1.73 m2 63.6 (47.182.7) 51.5 (36.871.1) 42.4 (30.461.2)
#30 176 (5.7) 141 (13.6) 161 (24.0)
>30 to #60 1,189 (38.4) 508 (49.2) 330 (49.1)
>60 1,707 (55.1) 378 (36.6) 179 (26.6)
Assigned study treatment
Vericiguat 1,550 (50.0) 526 (50.9) 338 (50.3)
Placebo 1,550 (50.0) 507 (49.1) 334 (49.7)
MAGGIC risk score 22 (1827) 26 (2130) 27 (2332)
Values are median (25th to 75th percentile) or n (%).
ACE-I ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary
disease; eGFR ¼ estimated glomerular filtration rate; HF ¼ heart failure; ICD ¼ implantable cardioverter-defibrillator; IV ¼ intravenous; MAGGIC ¼ Meta-Analysis Global Group in Chronic
Heart Failure; MRA ¼ mineralocorticoid receptor antagonist; NT-proBNP ¼ N-terminal proB-type natriuretic peptide; NYHA ¼ New York Heart Association.
J A C C : H E A R T F A I L U R E V O L . 8 , N O . 1 1 , 2 0 2 0 Ezekowitz et al.
N O V E M B E R 2 0 2 0 : 9 3 1 – 9 NT-proBNP and Outcomes in VICTORIA
935the highest quartile (e.g., median MAGGIC risk score
of 27). Patient characteristics and the treatment effect
according to the components of the primary com-
posite endpoint are available in Supplemental
Tables 4A and 4B.
ASSOCIATION OF NT-proBNP WITH CLINICAL OUTCOMES.
When the overall association between NT-proBNP
values at randomization and the risk of the primary
composite outcome was assessed, we observed an
excess hazard per doubling of NT-proBNP with and
without adjustment for the MAGGIC risk score
(Table 3). This relationship was more pronounced in
patients assigned to vericiguat compared with those
assigned to placebo. Similar results were observed for
CVD and HFH. These findings were confirmed after
adjustment for prediction models developed in the
VICTORIA trial (Supplemental Table 5).
DISCUSSION
The principal novel finding of the present study was
that the treatment effect of vericiguat compared
with placebo on the primary composite endpoint
was greatest in patients with NT-proBNP
levels <8,000 pg/ml at randomization, which was
further amplified if these levels were <4,000 pg/ml.
The benefit of vericiguat in this high-risk HF popu-
lation appeared to be clinically meaningful in both
relative and absolute terms and extended to both
the CVD and HFH components of the primaryoutcome. Although patients with higher NT-proBNP
levels within the range up to 8,000 pg/ml had
several clinical features indicative of higher risk, the
treatment effect associated with vericiguat
compared with placebo persisted after risk adjust-
ment for many of these factors. Our findings—using
all the natriuretic peptide data as a continuous var-
iable—provided further insight into that provided
from the initial pre-specified NT-proBNP quartile
subgroups and suggested the potential for a broader
range of patients who could benefit from treatment.
Moreover, there appeared to be amplification of that
benefit for patients whose entry NT-proBNP levels
were <4,000 pg/ml and who represented most of the
study population. These findings might be useful in
informing clinicians about how best to apply this
new treatment in the growing population of patients
with HFrEF with recent worsening of their status,
despite receiving good guideline-based therapies.
Patients enrolled in the VICTORIA trial were at
higher baseline risk for hospitalization or death
compared with patients in contemporary clinical trials
in HF, as evident by the median baseline NT-proBNP
concentration of 2,816 pg/ml, and they were general-
izable to the broader HFrEF population (9). In this trial
population at such high risk for clinical events, NT-
proBNP was predictive of the primary outcomes of
CVD or first HFH, concordant with previous trials and
other patient cohorts. This analysis also identified that
this association between NT-proBNP and clinical
CENTRAL ILLUSTRATION Treatment Effect of Vericiguat Compared With Placebo



























































































































































































































Ezekowitz, J.A. et al. J Am Coll Cardiol HF. 2020;8(11):931–9.
Treatment effect of vericiguat compared with placebo across the range of N-terminal pro–B-type natriuretic peptide (NT-proBNP) at randomization for the (A) primary
composite outcome, (B) cardiovascular death, or (C) heart failure hospitalization. Left-axis treatment effect expressed as hazard ratio (HR) (red line) with 95%
confidence intervals (CIs) (red shaded area) adjusted for the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score. Vertical shaded bars indicate the
number of patients within each NT-proBNP measurement bracket, expressed as a percentage on the right vertical axis. The presented values are from a back-
transformation of log-transformed NT-proBNP, and the x-axis is truncated at 32,000 pg/ml for presentation only.
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TABLE 2 Associations of the Study Treatment With the Primary Composite Endpoint According to NT-proBNP at Randomization Below/Above 4,000 and
8,000 pg/ml












(V vs. P)* HR (95% CI)
#4,000 (n ¼ 3,100) >4,000 (n ¼ 1,705)
CVD/HFH 28.4 21.6 6.8 61.4 64.7 3.3
Unadjusted 0.77 (0.670.88) 1.06 (0.931.21)
Adjusted 0.77 (0.680.88) 1.05 (0.921.20)
CVD 5.2 3.9 1.3 16.9 18.5 1.6
Unadjusted 0.75 (0.600.93) 1.12 (0.931.33)
Adjusted 0.75 (0.600.94) 1.10 (0.921.31)
HFH 23.2 17.7 5.5 44.6 46.2 1.6
Unadjusted 0.77 (0.670.89) 1.05 (0.901.23)
Adjusted 0.78 (0.670.90) 1.05 (0.901.22)
£8,000 (n [ 4,133) >8,000 (n [ 672)
CVD/HFH 33.7 28.3 5.4 74.5 87.2 12.7
Unadjusted 0.85 (0.760.94) 1.16 (0.951.42)
Adjusted 0.85 (0.760.95) 1.16 (0.941.41)
CVD 6.9 6.1 0.8 22.9 26.5 3.6
Unadjusted 0.85 (0.721.00) 1.34 (1.031.73)
Adjusted 0.84 (0.710.99) 1.32 (1.011.71)
HFH 26.8 22.2 4.6 51.6 60.7 9.1
Unadjusted 0.84 (0.750.94) 1.18 (0.931.49)
Adjusted 0.84 (0.750.95) 1.17 (0.921.48)
*All study treatment interactions were statistically significant (p < 0.05).
ARR ¼ absolute risk reduction; CI ¼ confidence interval; CVD ¼ cardiovascular death; HFH ¼ heart failure hospitalization; HR ¼ hazard ratio; p ¼ placebo; V ¼ vericiguat; other abbreviation as in Table 1.
J A C C : H E A R T F A I L U R E V O L . 8 , N O . 1 1 , 2 0 2 0 Ezekowitz et al.
N O V E M B E R 2 0 2 0 : 9 3 1 – 9 NT-proBNP and Outcomes in VICTORIA
937outcomes was not linear by revealing a much steeper
increment in the relationship for values>4,000 pg/ml.
This finding deserves consideration in future clinical
trials or cohort studies that will estimate prognosis and
evaluate new therapies.TABLE 3 Associations of Log-Transformed NT-proBNP at Randomizat
Study Treatment
Unadjusted HR (95% CI) per NT-proBNP
Doubling (pg/ml)* p Value† p fo
CVD/HFH








All patients 1.35 (1.301.41) <0.0001
Placebo 1.28 (1.211.35)
Vericiguat 1.43 (1.361.51)
*Unadjusted estimates in 4,805 patients. †HR (95% CI) and p value for log-transformed
transformed NT-proBNP at randomization with assigned study treatment. §Estimates ad
Abbreviations as in Tables 1 and 2.A secondary analysis of the PARADIGM-HF (Pro-
spective Comparison of ARNI with ACEI to Determine
Impact on Global Mortality and Morbidity in
Heart Failure) trial identified that NT-proBNP levels
before and after run-in, as well as 1 month afterion With Clinical Outcomes in Patients and According to Assigned
r Interaction‡
Adjusted HR (95% CI) per NT-proBNP
Doubling (pg/ml)§ p Value† p for Interaction‡
0.001 1.36 (1.311.41) <0.0001 0.002
1.29 (1.231.35)
1.43 (1.361.51)
0.012 1.50 (1.431.58) <0.0001 0.015
1.41 (1.311.52)
1.60 (1.491.71)
0.003 1.29 (1.241.34) <0.0001 0.005
1.22 (1.151.29)
1.36 (1.291.44)
NT-proBNP as a main effect only in the model. ‡HR (95% CI) and p value for the interaction of log-
justed for the MAGGIC Risk Score in 4,734 patients.
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clinical outcomes (10). However, there was no inter-
action between baseline NT-proBNP and treatment
efficacy in that study. A subsequent Swedish registry
in patients with HFrEF analyzed at hospital discharge
or as outpatients showed median NT-proBNP levels of
2,640 pg/ml (75% of patients had a NT-proBNP
of <5,914 pg/ml) (11). This study also demonstrated
higher cardiovascular event rates, defined as cardio-
vascular hospitalization or CVD, with increasing NT-
proBNP values.
The VICTORIA trial did not have a run-in phase,
and the values at randomization were similar to the
baseline values in other studies (e.g., GUIDE-IT
[Guiding Evidence Based Therapy Using Biomarker
Intensified Treatment in Heart Failure]),which had a
median baseline NT-proBNP of 2,653 pg/ml (12). This
comparison was particularly relevant because the
primary event rate of 35% in GUIDE-IT (using the
same primary endpoint) identified a similarly high-
risk population. Other contemporary trials,
including DAPA-HF (Dapagliflozin and Prevention of
Adverse Outcomes in Heart Failure) and PARADIGM-
HF, had median NT-proBNP values of 1,437 pg/ml
and 1,615 pg/ml, respectively, and primary endpoint
rates less than one-half of that observed in the VIC-
TORIA trial (11).
STUDY STRENGTHS AND LIMITATIONS. We studied
a large event-rich population with carefully adjudi-
cated clinical outcomes and NT-proBNP values
centrally measured in a core laboratory. Although we
chose not to impute values for the 245 patients
missing NT-proBNP levels at randomization, there
were no substantive differences between those pa-
tients and the overall cohort, and their omission was
unlikely to have affected our results (Supplemental
Table 1). The present study was an extension of
the pre-specified subgroup analysis of the primary
outcomes by quartiles of NT-proBNP and allowed for
the thorough examination of this relationship across
the full spectrum of NT-proBNP, which was broad
(10 to 175,000 pg/ml). The relationship among higher
NT-proBNP levels, reduced vericiguat efficacy, and
poorer outcomes might be related to diverse factors,
including patient illness severity, adequacy of
guideline-based therapy, activation of neuroendo-
crine pathways involved in HF pathophysiology, or
blunting of guanylate cyclase responsiveness in
advanced HF. This characterization of continuous
NT-proBNP informed the additional subgroups ofNT-proBNP and should be viewed as hypothesis-
generating in the context of the overall trial re-
sults. Finally, we adjusted for known determinants
of NT-proBNP, but as with all secondary analyses,
there might be unmeasured confounders.
CONCLUSIONS
In patients enrolled in the VICTORIA trial, NT-proBNP
at randomization was predictive of the primary and
secondary outcomes. Patients with an NT-
proBNP <8,000 pg/ml had both a reduction in the
primary outcome and its 2 components, CVD and
HFH, which identified a patient cohort who had ver-
iciguat might be beneficial.
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